Identification of Herpes Simplex Virus (HSV) Shedding in the Female Genital Tract of Pregnant and Nonpregnant Women by GeneXpert PCR, Routine PCR, and Culture

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT01878383
Recruitment Status : Recruiting
First Posted : June 14, 2013
Last Update Posted : February 8, 2019
Information provided by (Responsible Party):
David Kimberlin, MD, University of Alabama at Birmingham

Brief Summary:
PCR detection of HSV DNA shedding in the female genital tract using the GeneXpert system (Cepheid, Sunnyvale CA) will be compared with traditional (routine) PCR (pregnant and nonpregnant women) and with HSV culture (nonpregnant women). The GeneXpert system performs all sample-processing steps and real-time PCR in a single integrated cartridge. The standard cartridge is an inexpensive disposable plastic cartridge with filtration and ultrasonic lysis capabilities. It consists chiefly of several combined molded plastic components: a cartridge body containing eleven fluid reservoirs or chambers along with an attached PCR tube, a specialized valve body with an ultrasonic interface containing a sub-micron filter and glass lysis beads, and a rotary valve with an axial syringe barrel. The operation of the cartridge is simple. The rotary valve contains an inlet and an outlet port. Fluid such as a sample buffer can be drawn up into a syringe drive through the inlet port of the rotary valve and then dispensed into any other chamber within the cartridge by rotating the valve and expelling the fluid through the outlet port. The fluid can either be passed through a filter contained within the valve assembly or it can be passed directly into the next chamber without filtration, depending on the path that is chosen. The cartridge fluidics and subsequent real-time PCR all are performed within the GeneXpert instrument. The GeneXpert contains multiple modules (ICORE units) that can be independently programmed to drive the syringe/rotary valve, and to perform four-color real-time PCR. Each cartridge fits inside one module, and all processing, PCR, and analysis steps are performed automatically. Each ICORE module can be run and analyzed independently, so batching of samples is unnecessary.

Condition or disease Intervention/treatment
Herpes Simplex Virus Device: Genexpert assay

Detailed Description:

The GeneXpert HSV PCR test will be validated against HSV viral cultures and routine quantitative PCR. Validation will occur in two populations: 1) nonpregnant women in STI clinics with clinically-apparent HSV lesions (Group 1, n=300), and 2) pregnant women in active labor with no visible evidence of HSV infection (Group 2, n=12,500). All testing of samples on the GeneXpert platform, routine quantitative PCR, and viral culture will be done at the UAB Central Laboratory. Women in each group will have specimens obtained from genital lesions (Group 1) or vaginal swabs (Group 2). Specimens from all women in Group 1 will be evaluated by HSV culture, routine HSV PCR, and GeneXpert HSV PCR. Approximately half of the women in Group 2 will be tested by routine HSV PCR and GeneXpert HSV PCR; specimens from the rest of the women in Group 2 will be stored for possible testing in the future by routine HSV PCR and GeneXpert HSV PCR. In this manner, we will maximize the data from which to compare GeneXpert PCR results with routine PCR, while maintaining flexibility to ensure an adequate number of specimens are positive for HSV DNA by routine PCR.

Swabs from pregnant women in labor will be placed in viral transport media, frozen at -20°C, and batch-shipped to the UAB Central Laboratory for analysis on the GeneXpert instrument and by routine HSV quantitative PCR. Swabs from nonpregnant women in STI clinics will be placed in viral transport media, refrigerated at 4°C, and shipped to the UAB Central Laboratory for real time analysis on the GeneXpert instrument and by HSV culture and routine quantitative HSV PCR. Specimens from the first 300 women enrolled in Group 2 will be run as individual routine PCRs and in batches of 5 samples per PCR run. In this manner, we will validate that the level of detection from batching of samples for routine PCR is acceptable. Once this validation occurs, specimens from the approximately half of remaining Group 2 women will be batched for real-time routine PCR analysis. If a batch run of 5 specimens is negative, no further testing will be performed. If a batch run of 5 specimens is positive, all of the specimens will be separated out for re-running as individual PCRs. All specimens evaluated by routine PCR will also be evaluated by GeneXpert PCR; in this manner, we will have individual routine PCR results results for comparison against GeneXpert PCR results.

A blood specimen will be obtained from each nonpregnant (Group 1) and pregnant (Group 2) woman at the time of enrollment, and if she is determined to be shedding HSV by routine PCR, GeneXpert PCR, or culture then type-specific serologic testing will be performed. Correlation of viral typing from the virologic sampling with HSV-1 and HSV-2 serostatus will allow for categorization of infection (first-episode primary, first-episode nonprimary, or recurrent infection).

Those women in Group 1 who have a positive HSV culture will be contacted directly when the result is known. Women in Group 2 with a positive HSV PCR result will not be contacted because routine HSV PCR and GeneXpert PCR are not FDA-cleared tests in this population; thus, we will not know the test performance characteristics (e.g., sensitivity, specificity, etc.) until completion of the trial. All pregnant women in Group 2 will receive written materials at the time of enrollment educating them on signs and symptoms of neonatal HSV disease. All postpartum women will be contacted by telephone 60-90 days post-delivery and an inquiry will be made to determine if their babies developed neonatal HSV disease.

Data on the incidence of neonatal HSV disease among babies delivered to women in Group 2 will be compared with the incidence data from Brown et al.1 In their study of almost 60,000 women conducted over a 20 year period, this group of researchers has reported an incidence rate for neonatal HSV disease of 1 in 3,200 live births.

Study Type : Observational
Estimated Enrollment : 12700 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Device Trial: Identification of Herpes Simplex Virus (HSV) Shedding in the Female Genital Tract of Pregnant and Nonpregnant Women by GeneXpert PCR, Routine PCR, and Culture
Actual Study Start Date : January 2014
Estimated Primary Completion Date : September 2019
Estimated Study Completion Date : September 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Herpes Simplex

Group/Cohort Intervention/treatment
Non-pregnant women/active HSV lesions
Women presenting to local health department
Device: Genexpert assay
Pregnant women/no active HSV lesions
Women presenting in active labor
Device: Genexpert assay

Primary Outcome Measures :
  1. Sensitivity of detection of HSV DNA by GeneXpert PCR from specimens obtained from the genital tract of pregnant women in active labor or of non-pregnant women in STI clinics, as compared with routine PCR detection of viral DNA (pregnant and nonpregnant [ Time Frame: on day of enrollment ]
    assessing the vaginal specimen collected via a swab at the time of reported active labor with standard PCR compared to the assay of new device called a GeneXpert

Secondary Outcome Measures :
  1. HSV disease among neonates delivered to women without active genital HSV lesions Specificity, positive predictive value, and negative predictive value of detection of HSV DNA by GeneXpert PCR from specimens obtained from the genital tract of pregnant [ Time Frame: day of enrollment ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   19 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Pregnant and non-pregnant women

Inclusion Criteria:•Signed Informed Consent from woman

•≥ 19 years of age

  • Female gender
  • In active labor with a viable fetus, OR non-pregnant and being evaluated in STI clinics for herpetic genital lesions

Exclusion Criteria:•For women in active labor, active herpetic lesions in the genital region

  • Receipt of acyclovir, valacyclovir, or famciclovir within the previous 14 days
  • Known HIV infection

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01878383

Contact: Ilet Dale, RN 205-934-2424
Contact: Linda Austin 205-934-2424

United States, Alabama
University of Alabama at Birmingham Recruiting
Birmingham, Alabama, United States, 35233
Contact: David Kimberlin, M.D.    205-934-5316   
Principal Investigator: David Kimberlin, M.D.         
United States, Arkansas
University of Arkansas for Medical Sciences Completed
Little Rock, Arkansas, United States, 72202
United States, Colorado
University of Colorado at Denver Health Sciences Center Completed
Aurora, Colorado, United States, 80045
United States, District of Columbia
Children's National Medical Center Completed
Washington, District of Columbia, United States, 20010
United States, Georgia
Emory Children's Center Completed
Atlanta, Georgia, United States, 30322
United States, Louisiana
Louisiana State University Health Science Center-Shreveport Completed
Shreveport, Louisiana, United States, 71103
United States, Missouri
Washington University in St Louis School of Medicine Terminated
Saint Louis, Missouri, United States, 63110
United States, New Hampshire
Dartmouth Medical School Terminated
Lebanon, New Hampshire, United States, 03756
United States, New York
Steven & Alexandra Cohen Children's Medical Center of New York (CCMC) Terminated
Manhasset, New York, United States, 11030
University of Rochester Medical Center Completed
Rochester, New York, United States, 14642
United States, North Carolina
Carolinas Medical Center - Charlotte Completed
Charlotte, North Carolina, United States, 28203
United States, Ohio
MetroHealth Medical Center Completed
Cleveland, Ohio, United States, 44109
Nationwide Children Hospital Completed
Columbus, Ohio, United States, 43205-2664
United States, Pennsylvania
McGee Women's Hospital Completed
Pittsburgh, Pennsylvania, United States, 15224
United States, Utah
University of Utah School of Medicine Terminated
Salt Lake City, Utah, United States, 84132
Sponsors and Collaborators
University of Alabama at Birmingham
Principal Investigator: David W Kimberlin, MD University of Alabama at Birmingham
Principal Investigator: Richard Whitley, MD University of Alabama at Birmingham

Responsible Party: David Kimberlin, MD, Principal Investigator, University of Alabama at Birmingham Identifier: NCT01878383     History of Changes
Other Study ID Numbers: DMID 11-0070
First Posted: June 14, 2013    Key Record Dates
Last Update Posted: February 8, 2019
Last Verified: February 2019

Keywords provided by David Kimberlin, MD, University of Alabama at Birmingham:

Additional relevant MeSH terms:
Herpes Simplex
Herpesviridae Infections
DNA Virus Infections
Virus Diseases
Skin Diseases, Viral
Skin Diseases, Infectious
Skin Diseases